A: Patients receive gemcitabine(1,000 mg/m2, day1,8) plus S-1(60-100 mg/day, day1-14) every 3 weeks. It is repeated until obvious evidence of disease progression, patient refusal, or unacceptable toxi
Sponsors
Japan Clinical Oncology Group(JCOG), Tokai University Hospital Kanagawa Cancer Center
Conditions
advanced pancreatic cancerbiliary tract neoplasm
Phase 2
Randomized phase II study of gemcitabine and S-1 combination therapy versus S-1 in advanced biliary tract cancer. (JCOG 0805)
Active, not recruitingJPRN-UMIN000001685
Start: 2009-02-01Target: 100Updated: 2026-06-29
Randomized phase II study of gemcitabine and S-1 combination therapy versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer
RecruitingJPRN-UMIN000007173
Start: 2012-02-01Target: 90Updated: 2026-06-29